Chordate Medical Holding AB's (publ) ("Chordate") Board of Directors has today decided to convene an Extraordinary General Meeting. The reason for the Extraordinary General Meeting is to decide on the election of a new Board member, Caroline Lundgren Brandberg, a decision on the establishment of a Nomination Committee and a decision on a new option program for key persons in the company. The formal notice must be published no later than September 21st, where full information on each decision point will be included.
The Board's decision to convene an Extraordinary General Meeting relates to three matters. Shareholders representing more than 50 percent of the ownership propose that Caroline Lundgren Brandberg take a seat on the board. The matter of the Nomination Committee intends to formalize such a review body before the next Annual General Meeting. The option program is intended to give the company the opportunity to be able to attract and retain the right competence in the company.
This disclosure was submitted for publication, through the contact person below, on September 14th 2021 at 16:40 am CET.
For more information, please contact:
Anders Weilandt, VD
anders.weilandt@chordate.com
Phone: +46 (0) 733 87 42 77
The following documents can be retrieved from beQuoted
The-Board-decides-to-convene-an-Extraordinary-General-Meetin.pdf
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more athttps://www.chordate.com/en/
